Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (NCT07214779)
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Who can join: Review the eligibility criteria below.
Location: Alaska Womens Cancer Care Akwcc — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (181 Sites)
Showing the first 25 of 181 sites.
- Alaska Womens Cancer Care Akwcc — Anchorage, Alaska
- University of Arizona Cancer Center — Tucson, Arizona
- City of Hope Medical Center — Duarte, California
- Providence Medical Foundation — Fullerton, California
- University of California, San Diego-Moores Cancer Center — La Jolla, California
- Valkyrie Clinical Trials — Los Angeles, California
- Uci Health Chao Family Comprehensive Cancer Center — Orange, California
- Ventura County Hematology Oncology Specialists-Oxnard — Oxnard, California
- University of Colorado Cancer Center — Aurora, Colorado
- Brcr Global — Miramar, Florida
- Winship Cancer Institute At Emory University — Atlanta, Georgia
- Georgia Cancer Center — Augusta, Georgia
- Carle Cancer Center — Effingham, Illinois
- Northshore University Health System-Evanston Hospital — Evanston, Illinois
- City of Hope - Chicago Cancer Center — Zion, Illinois
- St Elizabeth Healthcare — Edgewood, Kentucky
- Women'S Cancer Care — Covington, Louisiana
- Maine Center For Cancer Medicine — Scarborough, Maine
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins — Baltimore, Maryland
- Holy Cross Hospital — Silver Spring, Maryland
- Mercy Hospital St. Louis - David C. Pratt Cancer Center — St Louis, Missouri
- Billings Clinic — Billings, Montana
- Women'S Cancer Center of Nevada — Las Vegas, Nevada
- Center of Hope — Reno, Nevada
- Unm Comprehensive Cancer Center — Albuquerque, New Mexico
📞 Contact the Study Coordinator
Phone: (855) 463-3463
Email: medinfo@incyte.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.